This page separates registry-reported design information from statistical interpretation. The ClinicalTrials.gov record provides the official trial registry record.
1. Trial at a Glance
The COAT Trial was a phase 4, single-group clinical study evaluating cyclosporine ophthalmic solution in participants with dry eye. The study enrolled 52 participants and assessed change in corneal high order aberrations after treatment.
| Feature | COAT Trial |
|---|---|
| ClinicalTrials.gov identifier | NCT06482177 |
| Title | The COAT Trial: Cequa's Onset of Action Trial |
| Status | COMPLETED |
| Condition | Dry Eye |
| Phase | 4 |
| Enrollment | 52 |
| Intervention | Cyclosporine ophthalmic solution (drug) |
| Primary endpoint | Change in corneal high order aberrations (HOA) |
2. Clinical Question
The central question of the COAT Trial was whether treatment with cyclosporine ophthalmic solution was associated with measurable changes in corneal high order aberrations after 7, 14, and 28 days of treatment in participants with dry eye.
Population
Participants with the condition of dry eye enrolled in a phase 4 treatment study.
Intervention
Cyclosporine ophthalmic solution (drug).
Comparator
The registry describes a single-group design; no comparator arm is reported.
Primary question
How does corneal high order aberration change after 7, 14, and 28 days of treatment?
3. Trial Design
| Design feature | Description |
|---|---|
| Study type | Single-group treatment study |
| Number of arms | 1 |
| Enrollment | 52 |
| Start date | 2023-10-12 |
| Primary completion date | 2024-06-05 |
4. Primary Endpoint
| Endpoint | Time frame | Description |
|---|---|---|
| Change in corneal high order aberrations (HOA) | After 7, 14, and 28 days of treatment | Change in corneal HOA |
5. Planned Analysis
The ClinicalTrials.gov record identifies the primary endpoint as change in corneal high order aberrations after 7, 14, and 28 days of treatment. No results are posted on ClinicalTrials.gov.
For a repeated measurement endpoint collected over multiple treatment time points, a statistical analysis would typically compare measurements over time using methods appropriate for longitudinal data. Depending on the measurement structure and assumptions, approaches may include repeated-measures models, mixed-effects models, or other methods designed to account for correlation among observations from the same participant.
Primary endpoint
Measured after 7, 14, and 28 days of treatment
6. Statistical Methodology
Single-group longitudinal analysis
Because the registry describes a single-group design, the statistical question differs from a randomized comparison. The analysis focuses on change within participants over time rather than estimating a treatment difference between independent groups.
Repeated observations from the same participant are usually correlated. Statistical methods must account for this within-participant dependence.
Repeated measurements
The primary endpoint includes measurements after 7, 14, and 28 days of treatment. Longitudinal methods allow investigators to evaluate whether measurements change across multiple follow-up visits while considering the repeated nature of the data.
Change from baseline
A common clinical-trial approach for continuous outcomes is to evaluate the difference between follow-up measurements and baseline measurements. The interpretation depends on the direction of clinically meaningful change for the specific measurement.
7. Statistical Methods Explained
Why is this trial analyzed differently from a randomized trial?
The registry describes a single-group design with one intervention. Without a separate comparator group, the analysis evaluates within-participant change rather than a randomized treatment effect.
Why are measurements taken after 7, 14, and 28 days?
Multiple follow-up measurements allow investigators to examine how the endpoint changes over the treatment period rather than relying on a single observation.
Why are repeated-measures methods useful?
Measurements from the same participant are generally more similar to each other than measurements from different participants. Statistical models account for this correlation.
What does a change in corneal HOA represent statistically?
It represents a difference in the measured corneal high order aberration value over time. The clinical meaning depends on the magnitude, variability, and relationship of the change to patient outcomes.
8. Important Limitations and Interpretation Issues
- No randomized comparator: The single-group design does not estimate a randomized difference between cyclosporine ophthalmic solution and another treatment or control condition.
- No posted results: The registry does not report outcome estimates, confidence intervals, or p-values for the primary endpoint.
- Sample size: The study enrolled 52 participants, which affects the precision of estimated changes.
- Longitudinal assumptions: Repeated-measures analyses require appropriate handling of within-participant correlation and missing observations.
- Clinical interpretation: Statistical change in an optical measurement should be interpreted separately from broader clinical outcomes.
9. Why This Trial Matters Statistically
The COAT Trial is a useful example of how statistical analysis differs between randomized comparative studies and single-group longitudinal studies.
| Concept | How it appears in COAT Trial |
|---|---|
| Single-group design | One intervention group with 52 participants |
| Longitudinal measurement | Endpoint assessed after 7, 14, and 28 days of treatment |
| Continuous outcome analysis | Change in corneal high order aberrations |
| Within-participant correlation | Repeated observations from the same participants require appropriate modeling |
| Interpretation limits | No randomized comparator for treatment-effect estimation |
10. Primary Sources
- ClinicalTrials.gov: NCT06482177.
Continue through the Clinical Biostats knowledge graph
Explore clinical trial methods, statistical concepts, and analysis workflows.
11. Record Summary
The COAT Trial is a completed phase 4, single-group treatment study evaluating cyclosporine ophthalmic solution in dry eye. The registry identifies change in corneal high order aberrations after 7, 14, and 28 days of treatment as the primary endpoint. The statistical interpretation centers on longitudinal measurement, within-participant change, and the limitations of drawing comparative treatment conclusions from a single-group design.